Literature DB >> 33942924

Clinical Profiles and Mortality of COVID-19 Inpatients with Parkinson's Disease in Germany.

Raphael Scherbaum1, Eun Hae Kwon1, Daniel Richter1, Dirk Bartig2, Ralf Gold1,3, Christos Krogias1, Lars Tönges1,3.   

Abstract

BACKGROUND: Comprehensive, nationwide data regarding Parkinson's disease (PD) hospitalizations, coronavirus disease 2019 (COVID-19) in-hospital frequency, and COVID-19-associated inpatient mortality during the first wave of the COVID-19 pandemic are not available.
OBJECTIVE: To provide a nationwide analysis on hospitalized PD patients in Germany and evaluate the impact of the COVID-19 pandemic.
METHODS: We conducted a cross-sectional study using an administrative claims database covering 1468 hospitals and 5,210,432 patient hospitalizations including a total of 30,872 COVID-19+ cases between January 16 and May 15, 2020.
RESULTS: Compared to 2019, hospitalizations for PD transiently decreased by up to 72.7% in 2020. COVID-19 frequency was significantly higher in the population of 64,434 PD patients (693 being COVID-19+ ) than in non-PD patients (1.1% vs. 0.6%, P < 0.001), especially in subjects with advanced age (≥ 65 years). Regarding established COVID-19 risk comorbidities, COVID-19+ inpatients with PD showed higher incidences than non-PD COVID-19+ subjects, particularly hypertension and chronic kidney disease. Advanced age and male sex were significantly more frequent in COVID-19+ than in COVID-19- PD patients. The COVID-19 inpatient mortality rate was much higher in PD patients than in non-PD patients (35.4% vs. 20.7%, P < 0.001), especially in patients aged 75-79 years. Of note, overall inpatient mortality of PD patients was significantly higher in 2020 than in 2019 (5.7% vs. 4.9%, P < 0.001).
CONCLUSIONS: PD inpatients are more frequently affected by COVID-19 and suffer from increased COVID-19-associated mortality in comparison to non-PD patients. More comprehensive studies are needed to assess the significance of associated comorbidities for COVID-19 risk and mortality in PD.
© 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  COVID-19 mortality; COVID-19 risk factors; Parkinson's disease; epidemiology; hospitalization

Mesh:

Year:  2021        PMID: 33942924     DOI: 10.1002/mds.28586

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  16 in total

1.  Mental and neurological disorders and risk of COVID-19 susceptibility, illness severity and mortality: A systematic review, meta-analysis and call for action.

Authors:  Lin Liu; Shu-Yu Ni; Wei Yan; Qing-Dong Lu; Yi-Miao Zhao; Ying-Ying Xu; Huan Mei; Le Shi; Kai Yuan; Ying Han; Jia-Hui Deng; Yan-Kun Sun; Shi-Qiu Meng; Zheng-Dong Jiang; Na Zeng; Jian-Yu Que; Yong-Bo Zheng; Bei-Ni Yang; Yi-Miao Gong; Arun V Ravindran; Thomas Kosten; Yun Kwok Wing; Xiang-Dong Tang; Jun-Liang Yuan; Ping Wu; Jie Shi; Yan-Ping Bao; Lin Lu
Journal:  EClinicalMedicine       Date:  2021-09-08

Review 2.  Role of SARS-CoV-2 in Modifying Neurodegenerative Processes in Parkinson's Disease: A Narrative Review.

Authors:  Jeremy M Morowitz; Kaylyn B Pogson; Daniel A Roque; Frank C Church
Journal:  Brain Sci       Date:  2022-04-22

3.  The effects of Alzheimer's and Parkinson's disease on 28-day mortality of COVID-19.

Authors:  M Fathi; F Taghizadeh; H Mojtahedi; S Zargar Balaye Jame; N Markazi Moghaddam
Journal:  Rev Neurol (Paris)       Date:  2021-09-13       Impact factor: 4.313

Review 4.  Parkinson's Disease and SARS-CoV-2 Infection: Particularities of Molecular and Cellular Mechanisms Regarding Pathogenesis and Treatment.

Authors:  Aurelian Anghelescu; Gelu Onose; Cristina Popescu; Mihai Băilă; Simona Isabelle Stoica; Ruxandra Postoiu; Elena Brumă; Irina Raluca Petcu; Vlad Ciobanu; Constantin Munteanu
Journal:  Biomedicines       Date:  2022-04-26

5.  Machine Learning Based Prediction of COVID-19 Mortality Suggests Repositioning of Anticancer Drug for Treating Severe Cases.

Authors:  Thomas Linden; Frank Hanses; Daniel Domingo-Fernández; Lauren Nicole DeLong; Alpha Tom Kodamullil; Jochen Schneider; Maria J G T Vehreschild; Julia Lanznaster; Maria Madeleine Ruethrich; Stefan Borgmann; Martin Hower; Kai Wille; Torsten Feldt; Siegbert Rieg; Bernd Hertenstein; Christoph Wyen; Christoph Roemmele; Jörg Janne Vehreschild; Carolin E M Jakob; Melanie Stecher; Maria Kuzikov; Andrea Zaliani; Holger Fröhlich
Journal:  Artif Intell Life Sci       Date:  2021-12-17

6.  Parkinson's disease related mortality: Long-term trends and impact of COVID-19 pandemic waves.

Authors:  Ugo Fedeli; Veronica Casotto; Claudio Barbiellini Amidei; Mario Saia; Silvia Netti Tiozzo; Cristina Basso; Elena Schievano
Journal:  Parkinsonism Relat Disord       Date:  2022-04-25       Impact factor: 4.402

7.  The impact of the COVID-19 pandemic on hospitalizations and plasmapheresis therapy in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide analysis from Germany.

Authors:  Daniel Richter; Simon Faissner; Dirk Bartig; Lars Tönges; Kerstin Hellwig; Ilya Ayzenberg; Christos Krogias; Ralf Gold
Journal:  Ther Adv Neurol Disord       Date:  2021-07-07       Impact factor: 6.570

8.  Parkinson's disease patients may have higher rates of Covid-19 mortality in Iran.

Authors:  Mehri Salari; Masoud Etemadifar; Farzad Ashrafi; Davood Ommi; Zahra Aminzade; Sepand Tehrani Fateh
Journal:  Parkinsonism Relat Disord       Date:  2021-07-08       Impact factor: 4.891

Review 9.  Can SARS-CoV-2 Infection Lead to Neurodegeneration and Parkinson's Disease?

Authors:  Lea Krey; Meret Koroni Huber; Günter U Höglinger; Florian Wegner
Journal:  Brain Sci       Date:  2021-12-18

10.  Impact of the COVID-19 Pandemic on Patients with Parkinson's Disease from the Perspective of Treating Physicians-A Nationwide Cross-Sectional Study.

Authors:  Andreas Wolfgang Wolff; Bernhard Haller; Antonia Franziska Demleitner; Erica Westenberg; Paul Lingor
Journal:  Brain Sci       Date:  2022-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.